Cargando…

Does Soluble TREM2 Protect Against Alzheimer's Disease?

Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) is a pattern recognition receptor on myeloid cells, and is upregulated on microglia surrounding amyloid plaques in Alzheimer's disease (AD). Rare, heterozygous mutations in TREM2 (e.g., R47H) increase AD risk several fold. TREM2 can be cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Guy C., St George-Hyslop, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Aging Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831327/ https://www.ncbi.nlm.nih.gov/pubmed/35153729 http://dx.doi.org/10.3389/fnagi.2021.834697

Ejemplares similares

The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer’s Disease
por: Zhong, Li, et al.
Publicado: (2019)

Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer’s Disease
por: Liu, Changan, et al.
Publicado: (2019)

Shifting the balance: soluble ADAM10 as a potential treatment for Alzheimer's disease
por: Hershkovits, Ayelet Sarah, et al.
Publicado: (2023)

The Association of CSF sTREM2 With Cognitive Decline and Its Dynamic Change in Parkinson's Disease: Analysis of the PPMI Cohort
por: Qin, Qixiong, et al.
Publicado: (2022)

Evidence of Filamin A loss of solubility at the prodromal stage of neuropathologically-defined Alzheimer’s disease
por: Aumont, Etienne, et al.
Publicado: (2022)

Corrigendum: Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2(*)R47H
por: Kotredes, Kevin P., et al.
Publicado: (2022)

Editorial: How does exercise modify the course of Alzheimer's disease?
por: Arciero, Paul J., et al.
Publicado: (2023)

TREM2 improves neurological dysfunction and attenuates neuroinflammation, TLR signaling and neuronal apoptosis in the acute phase of intracerebral hemorrhage
por: Liu, Sidan, et al.
Publicado: (2022)

Does Chronic Sleep Fragmentation Lead to Alzheimer's Disease in Young Wild-Type Mice?
por: Ba, Li, et al.
Publicado: (2021)

TREM2-Dependent Effects on Microglia in Alzheimer’s Disease
por: Zhou, Yingyue, et al.
Publicado: (2018)

A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease
por: Jayatunga, Dona P. W., et al.
Publicado: (2022)

A 16-Week Aerobic Exercise Intervention Does Not Affect Hippocampal Volume and Cortical Thickness in Mild to Moderate Alzheimer’s Disease
por: Frederiksen, Kristian Steen, et al.
Publicado: (2018)

Crystal Ball Health Policies: A Case Against Preventive Testing For Alzheimer’s Disease
por: Inglese, Silvia, et al.
Publicado: (2022)

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
por: Henjum, Kristi, et al.
Publicado: (2016)

TREM2 ectodomain and its soluble form in Alzheimer’s disease
por: Yang, Jiaolong, et al.
Publicado: (2020)

TREM2 in Alzheimer’s Disease: Microglial Survival and Energy Metabolism
por: Zheng, Honghua, et al.
Publicado: (2018)

Tau kinetics in Alzheimer's disease
por: Hier, Daniel B., et al.
Publicado: (2022)

Association of rs2062323 in the TREM1 gene with Alzheimer's disease and cerebrospinal fluid‐soluble TREM2
por: Wang, Zuo‐Teng, et al.
Publicado: (2023)

Alzheimer’s disease: an axonal injury disease?
por: Dan, Liang, et al.
Publicado: (2023)

The viral hypothesis in Alzheimer’s disease: SARS-CoV-2 on the cusp
por: Liu, Nanyang, et al.
Publicado: (2023)

Microglial autophagy in Alzheimer’s disease and Parkinson’s disease
por: Wang, Zhifu, et al.
Publicado: (2023)

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
por: Heslegrave, Amanda, et al.
Publicado: (2016)

The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer’s disease
por: Park, So-Hee, et al.
Publicado: (2021)

Alzheimer’s Disease: An Update and Insights Into Pathophysiology
por: Abubakar, Murtala Bello, et al.
Publicado: (2022)

Benefits of dietary polyphenols in Alzheimer’s disease
por: El Gaamouch, Farida, et al.
Publicado: (2022)

Redox signaling and metabolism in Alzheimer's disease
por: Holubiec, M. I., et al.
Publicado: (2022)

Editorial: Systemic implications of Alzheimer's disease
por: Cortes, Constanza J., et al.
Publicado: (2023)

Soluble Triggering Receptor Expressed on Myeloid Cells 2 From Cerebrospinal Fluid in Sleep Disorders Related to Parkinson’s Disease
por: Mo, Mingshu, et al.
Publicado: (2021)

Awareness for People With Alzheimer’s Disease: Profiles and Weekly Trajectories
por: Mayelle, Amandine, et al.
Publicado: (2022)

Contribution of “Genuine Microglia” to Alzheimer's Disease Pathology
por: Hashioka, Sadayuki, et al.
Publicado: (2022)

Ischemia as a common trigger for Alzheimer’s disease
por: Elman-Shina, Karin, et al.
Publicado: (2022)

Editorial: Progress of Translational Medicine in Alzheimer's Disease
por: Zhang, Can, et al.
Publicado: (2022)

Editorial: Improving memory deficits in Alzheimer's disease
por: Wang, Fushun, et al.
Publicado: (2022)

Alzheimer’s disease and epilepsy: An increasingly recognized comorbidity
por: Yang, Fei, et al.
Publicado: (2022)

Small-molecule drugs development for Alzheimer's disease
por: Yao, Weiwei, et al.
Publicado: (2022)

Editorial: Insights in Alzheimer's disease and related dementias
por: Ibáñez, Agustín, et al.
Publicado: (2022)

Editorial: Disease-modifying targets and strategies for Alzheimer's disease and Parkinson's disease
por: Gao, Xiaoya
Publicado: (2023)

The role of structural variations in Alzheimer’s disease and other neurodegenerative diseases
por: Wang, Hui, et al.
Publicado: (2023)

Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer’s disease?
por: Mirkin, Sophia, et al.
Publicado: (2023)

Age-Related Eye Diseases in Individuals With Mild Cognitive Impairment and Alzheimer's Disease
por: Chua, Jacqueline, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tum9lpsift6hkr3di7pct5h1r8